Background Platelet function may be abnormal in patients with atrial fibrillation (AF) and could be related to abnormal thrombogenesis. The aim of this cross-sectional study was to investigate new aspects of platelet biology in AF, predominantly focusing on platelet activation and the effects of concomitant antiplatelet and anticoagulant therapy. 
Introduction
Important insights into the pathophysiology of thrombus formation (thrombogenesis) in AF have confirmed the presence of a hypercoagulable state [1] . Nevertheless, many studies exploring the presence of a hypercoagulable state in AF have focussed on various clotting parameters (such as fibrin D-dimer and fibrinogen), and markers of endothelial damage or dysfunction (such as von Willebrand factor and soluble thrombomodulin), rather than on platelets per se [2] [3] [4] [5] . Whilst the benefits of antithrombotic therapy in preventing stroke in AF are being increasingly recognised, further developments in thromboprophylaxis are needed, especially as warfarin confers the inconvenience of regular anticoagulation monitoring and the benefits of aspirin are inconsistent. Thus, a comprehensive understanding of the role of platelet function as a key contributor towards the pathogenesis of thrombogenesis in AF has been relatively neglected [6] . A greater understanding of the role of platelets in AF may contribute to the development of new antiplatelet agents that may provide a viable alternative to warfarin or aspirin for thromboprophylaxis in AF.
The aim of the present study was to investigate different aspects of platelet function in AF, predominantly focusing on platelet activation and the effects of concomitant antiplatelet and anticoagulant therapy. We hypothesised that platelet activation is abnormal in patients with AF who were not taking antithrombotic therapy, and that these changes would be influenced by aspirin or warfarin. Our indices of platelet activation were ex vivo platelet aggregation and plasma levels of soluble glycoprotein V (i.e. sGPV). This latter molecule is normally a membrane constituent, so that increased levels in the plasma imply changes in platelet (patho) physiology, such as activation [7] [8] [9] . We also measured another marker of platelet physiology ( -thromboglobulin) known to be increased in AF [3, 4] . Differences in these platelet indices were compared by measurement of non-platelet indices of hypercoagulability (i.e. plasma levels of fibrinogen and fibrin D-dimer), also previously been shown to be abnormal in AF [3] [4] [5] to ensure that patients were indeed in a hypercoagulable state. The approach we took to testing our hypothesis was cross-sectional, observing different groups of patients not on therapy, and those already taking antiplatelet or anticoagulant drugs.
Patients and methods

Participants
The study group comprised of 238 patients with nonrheumatic AF, lasting at least 4 weeks before examination, confirmed electrocardiographically on at least two occasions, and 50 healthy controls in sinus rhythm. Patients with AF were divided into three subgroups: (i) patients on no antithrombotic therapy (n=93); (ii) patients established on aspirin (75-325 mg . day 1 , n=60); and (iii) patients established on dose-adjusted warfarin (International Normalised Ratio [INR] range 2·0-3·0, n=85). We excluded any patients with haematological, renal (creatinine >200 mg . dl 1 ), hepatic (liver enzymes >twice the upper limit of normal), inflammatory, neoplastic disorders and those who had suffered recent (<3 months) myocardial infarction or stroke, as these disorders might influence platelet activation and the level of the markers. Patients who consumed regular non-steroidal antiinflammatory drugs, corticosteroids or hormone replacement therapy and those on therapeutic doses of heparin were also excluded. Furthermore, patients with rheumatic mitral valvular disease, prosthetic cardiac valves and acute AF precipitated by thyrotoxicosis or any acute infection were excluded from the study. The study was approved by the City Hospital Ethics committee and written, informed consent was obtained.
Blood results in patients with AF were compared with 'healthy controls', which consisted of 50 normal subjects (23 men and 27 women; 70 13 years) recruited from healthy hospital staff, relatives of the patients and those attending for routine senile cataract surgery in the Eye Hospital. The subjects were non-smokers with no clinical evidence of vascular, metabolic, neoplastic, or inflammatory disease, on careful history, examination and routine laboratory tests. Clinically, these subjects were normotensive and in sinus rhythm. These healthy persons are included to provide a perspective for several of the laboratory results in the patients: no case/control study for fibrin D-dimer, or -thromboglobulin is implied as differences in these laboratory indices are already established in AF [3] [4] [5] . However, the controls are required to look for possible changes in platelet aggregation and sGPV.
Laboratory
Blood samples (approximately 10 ml) were drawn from an antecubital vein with atraumatic venepuncture into plastic tubes with 3·2% sodium citrate for platelet aggregation study, and also for the quantification of plasma sGPV, fibrinogen and fibrin D-dimer levels. Blood for plasma -thromboglobulin was taken into vacutainers containing citrate, theophylline, adenosine and dipyridamole (CTAD). Blood samples for the quantification of plasma markers were separated within 1 h of collection by centrifugation at 3000 rpm for 10 min. Aliquots were stored at 70 C to allow batch analysis. sGPV was quantified using an enzyme linked immunosorbent assay (ELISA) developed and validated in our laboratory [9] . -thromboglobulin levels (Asserachrom Diagnostica Stago, Asnieres Sur Seine, France) and fibrin D-dimer (Technoclone, Vienna/Wien, Austria) were determined by ELISA. Plasma fibrinogen (g . L 1 ) was measured by the Clauss technique on a Pacific Haemostasis (North Carolina, USA) coagulometer with bovine thrombin from Alpha Laboratories (Eastleigh, Hants, UK).
Citrated blood for platelet aggregation was maintained at room temperature (RT 22 C) until sample preparation, to minimise ex vivo platelet lysis or activation. Citrated blood tubes were centrifuged within 1 h of collection, at RT at 1000 rpm for 10 min. The supernatant, platelet rich plasma was separated. The residual sample was then centrifuged at 2000 rpm for 20 min to obtain a clear citrated supernatant, i.e. platelet free plasma. Ex-vivo platelet aggregation was measured in a plasma platelet aggregometer (Platelet aggregation profiler, model PAP-4, Bio/data corporation, Horsham, USA). Aggregation was induced by the addition of the following reagents: ADP (adenosine diphosphate, final concentration of 0·1 mol . ml 1 ), collagen (final concentration of 2 mg . ml 1 ), epinephrine (final concentration of 0·1 mol . ml 1 ) [Sigma Diagnostics, St. Louis, MO, USA] and thrombin (final concentration of 1 NIH units . ml 1 ) (Fisher Diagnostics, Pacific haemostasis, Huntersville, NC, USA). Platelet aggregation curves were recorded and the extent of platelet aggregation was evaluated by measuring the percentage platelet aggregation at the end of 3 min.
The intra-assay coefficient of all assays and platelet studies was <5%, inter-assay variation was <10%. All laboratory work was performed in blinded fashion with respect to the identity of the samples.
Power calculations
Based on our previous work and that of others [3] [4] [5] , we hypothesised an increase in sGPV to be of the same order of magnitude as an increase in fibrin D-dimer (our reference marker) in patients with AF compared to controls of 0·4 of a standard deviation. In order to achieve with this at P<0·05 and 1-=0·8, 50 subjects per groups are required. In comparing the three groups of patients, we hypothesised a difference of 0·33 of a standard deviation due to one of the antithrombotic drugs (i.e. aspirin or warfarin). In order to achieve this under the same conditions, we needed data from 60 subjects per group.
Statistical analysis
Continuous data were analysed by the Shapiro-Wilks test to determine distribution. Results are expressed as mean and standard deviation (SD) or as median and interquartile range (IQR) for the normally distributed data and skewed data respectively. Data between various subgroups of patients and controls was analysed by Kruskal-Wallis test or one-way ANOVA (on logged data, where appropriate), with Tukey's post-hoc analysis as appropriate. Correlations were performed by Pearson's correlation method (on logged data, where appropriate). All statistical calculations were performed on a microcomputer using a commercially available statistical package (Minitab release 12, Minitab Inc, PA, USA). A P value <0·05 was considered statistically significant for the cross-sectional analyses, except for the Pearson correlations, where a P value <0·01 was taken as statistically significant, in view of the many correlations performed.
Results
Clinical characteristics, including patient demography and associated medical conditions/risk factors of the study population are shown in Table 1 . Age and sex ratios were similar between patients with healthy controls and various subgroups of AF. The prevalence of the majority of clinical cardiovascular risk factors or diseases did not differ significantly between various subgroups of patients with AF, although AF patients on warfarin had a higher prevalence of ischaemic heart disease (IHD) and cardiac failure, when compared to AF patients on no antithrombotic therapy. Similarly, AF patients on aspirin had a higher prevalence of IHD and cardiac failure when compared to AF patients on no antithrombotic therapy. Patients with AF on doseadjusted warfarin therapy had a mean INR of 2·8 (SD 0·9).
Cross-sectional analyses
In the group of 93 patients not yet on therapy, there were increases in -thromboglobulin, fibrin D-dimer and sGPV levels, compared to controls; there were no differences in platelet count, fibrinogen or platelet aggregatory responses to the four agonists (Table 2) . Of these 93 patients, 17 had lone AF (i.e. AF and no other major risk factors or disease) and 76 had AF with other risk factors/clinical disease (that is, not 'lone AF'). Compared to the healthy controls, lone AF patients had raised D-dimer and sGPV but with reduced power the -thromboglobulin difference (although similar) lost significance (Table 2) . In comparing the lone AF patients with those AF patients with other disease/risk factors, AF=atrial fibrillation, IHD=ischaemic heart disease, CVA=cerebrovascular accident. ANOVA and Chi-squared test used as appropriate. *P<0·01 compared to both AF on warfarin and aspirin, **P=0·01 compared to AF on no therapy, ***P=0·02 compared to AF on no therapy.
and males and females, there were no significant differences in the measured indices apart from a higher mean platelet count in female patients (Table 3) . In comparing the three groups of patients (Table 4 ) patients established on warfarin had significantly lower plasma fibrin D-dimer levels. Those on aspirin had the highest plasma fibrin D-dimer levels, and aspirin significantly decreased platelet aggregation response to epinephrine.
Correlations and multivariate analysis
There were no significant correlations between the two plasma markers of platelet activation (that is, -thromboglobulin and sGPV) and platelet aggregation among healthy controls, AF patients on warfarin and AF patients on aspirin (data not shown, all P=ns). The aggregation responses to the different agonists also did not predict increased -thromboglobulin and sGPV levels, or fibrin D-dimer levels (data not shown, all P=ns). Multivariate analysis using stepwise multiple regression analysis was performed in the whole cohort of AF patients (including patients on no treatment, on aspirin and on warfarin) using fibrin D-dimer, plasma fibrinogen, -thromboglobulin and sGPV as dependent variables and age, sex, smoking status, presence of hypertension, IHD, cerebrovascular disease, diabetes mellitus, cardiac failure and antithrombotic therapy use (aspirin, warfarin, none) as predictors. The only significant finding was that sex was a predictor of plasma -thromboglobulin levels in patients with AF (P=0·006). In AF patients on no antithrombotic therapy, similar multivariate analysis using stepwise multiple regression analysis revealed the presence of IHD to be the only significant predictor of plasma sGPV levels (P=0·015). ( -TG=beta-thromboglobulin, AF=atrial fibrillation, ADP=adenosine diphosphate).
Results are expressed as mean standard deviation (SD) or as median with interquartile range (IQR) for the normally distributed data and skewed data respectively. Platelet aggregation expressed as median (interquartile range) percentage aggregation at 3 min. Data analysed by oneway ANOVA on logged data with Tukey's post-hoc analysis. *P<0·001 in comparison to other two groups, **P<0·001 in comparison to other two groups. ***P=0·01 compared to AF on no therapy.
Discussion
Increasing attention has been given to the role of prothrombotic or hypercoagulable state in AF, with the fulfilment of Virchow's triad for thrombogenesis in this condition [1, 2, [10] [11] [12] . The present study examines the role of various haematological factors in AF, with a special regard to platelet activation. We have comprehensively investigated different aspects of platelet activation in AF, that is, discharge of alpha granules ( -thromboglobulin), shedding of plasma membrane components (sGPV) and ex-vivo aggregation, and related these to fibrinogen and intravascular fibrin turnover (as reflected by fibrin D-dimer) which have previously been shown to be abnormal in AF [3] [4] [5] 12] . In addition, the present study reports for the first time, abnormal plasma levels of the platelet membrane surface glycoprotein, gp V (sGPV), in patients with AF, in keeping some degree of abnormal platelet function in AF.
It is not surprising that our AF patients on anticoagulant (warfarin) or antiplatelet (aspirin) therapy had significantly higher IHD and cardiac failure as these patients are at high-risk of thromboembolism. We accept that abnormal coagulation and platelet parameters may reflect more generalised vascular/heart disease or hypertension, rather than AF per se. However, the prothrombotic state in AF is independent of underlying structural heart disease or aetiology [1] and our AF patient subgroups are broadly comparable with respect to underlying aetiology or the associated conditions. Indeed, patients with lone AF had significantly higher plasma levels of fibrin D-dimer and sGPV when compared to healthy controls in sinus rhythm (Table 3) . Furthermore, when AF patients in the present study were analysed for the presence or absence of other cardiovascular disease/risk factors (Table 3) , there was no marked difference between the groups.
Plasma levels of -thromboglobulin, released from platelet alpha granules on activation and thus reflecting platelet activation, are higher in patients with both valvular and non-valvular AF [13] [14] [15] [16] [17] [18] . In the present study, we confirm these observations, and extend them in showing that levels are similar in the three subgroups of patients with AF ( Table 4 ), suggesting that neither warfarin nor aspirin influences this marker, and therefore, by surrogation, platelet activation. This suggests that the clinical benefit of warfarin in patients with AF is not mediated through reduction in platelet activation and thus indirectly suggests that platelet activation may not play a significant role in stroke and thromboembolism in AF. Indeed, aspirin has previously been shown not to affect alpha granule release in healthy smokers [19] . In support of this, previous studies have noted a possible association between -thromboglobulin and precursors of thromboembolism, but a definite association between platelet activation and stroke or thromboembolism in AF is far from certain. For example, AF itself, rather than the underlying risk factor(s) or disease, may result in platelet activation [17, 18, 20, 21] . Furthermore, enhanced platelet activation in AF when compared to sinus rhythm, with the prevalence of other vascular risk factors being comparable, and high plasma levels of -thromboglobulin in AF patients with or without stroke, have been described [21, 22] . More recently Black et al. [23] demonstrated that left atrial spontaneous echocontrast, considered to be a precursor of stroke, was not related to plasma -thromboglobulin or platelet count. Furthermore, platelet function (as -thromboglobulin) does not appear to be enhanced in the acute stage of cardioembolic stroke with non-valvular AF [24] . Finally, one of the largest studies investigating platelet activation in AF by measurement of plasma -thromboglobulin levels did not find an association with thromboembolism [25] . In the present study, platelet aggregation in response to majority of stimuli did not differ to a great extent between healthy controls and patients with AF (Table  2) , again casting doubt on the extent and significance of platelet activation in AF -which we have previously reviewed [6] . The non-uniform observations with respect to different markers of platelet activation could be due to the possibility that they represent different aspects of platelet activation [3] . In contrast, plasma fibrin D-dimer levels, marking both ongoing thrombogenesis and fibrin turnover [26] , was significantly higher in patients with AF, unless the patients were established on warfarin therapy. Indeed, the present study has confirmed previous observations [4] that warfarin significantly decreased plasma fibrin D-dimer levels in AF (even to levels below that seen in controls), implying that activation of the coagulation system, rather than platelets, was a crucial factor contributing to increased thromboembolic risk in AF and probably explains the more consistent beneficial effects of warfarin (acting on the coagulation system) rather than aspirin (acting on platelets) in AF.
Thus, abnormal platelet activity may be present in patients with AF, but it may not be an important mechanism leading to thromboembolism in AF. Instead, enhancement of the coagulation system in AF and the resulting thromboembolism may not actually be the result of platelet hyperfunction (that is, 'platelet-fibrin' thrombi), but rather of ''stasis-related'' thrombi formation. The absence of any beneficial effect of warfarin on plasma -thromboglobulin levels in the present study may suggest that platelet activation did not have a significant role in thromboembolism in AF. It is notable that our previous prospective study only found a marginal reduction in -thromboglobulin levels following the introduction of warfarin, which was of borderline significance [4] . Platelet glycoprotein V is an integral membrane surface molecule [27] cleavable by thrombin, thus releasing a soluble fragment. Although there is no simple relationship between thrombin-induced hydrolysis of sGPV and platelet activation [28] [29] [30] , it is suggested that the measurement of sGPV reflects activation of platelets in vivo and may be a useful marker for the diagnosis of thrombosis or prothrombotic states [31] . In the present study, plasma levels of sGPV were significantly higher in AF patients on no antithrombotic therapy, when compared to healthy controls. Furthermore, overall, IHD was a significant predictor of sGPV levels on stepwise multiple regression analysis, reflecting increased levels in atherosclerosis [32] . Once again, current treatment with warfarin and aspirin did not significantly influence sGPV levels.
The results from this study emphasise the complexity of the events of platelet activation in AF, although there is some uncertainty over the 'gold standard' method of assessing platelet activation and whether platelet aggregation (ex vivo) truly reflects platelet activation in vivo [6, 33] . We did not note any gender effect on platelet indices the subgroup analysis, although correcting for confounders on a multivariate analysis suggests that sex was a significant predictor for -thromboglobulin levels, in keeping with previous observations [34] . A definitive answer to the question of whether platelet activation exists in AF and if it is involved in thromboembolism in AF is far from simple and compares with the somewhat equivocal benefits of aspirin in AF in clinical trials [33] . Indeed, the present study would imply a high degree of non-responders to aspirin or aspirin resistance amongst patients with AF [33] . Future directions in this field should involve further clarification of the role of different aspects of platelet activation in AF and a clearer definition of the significance of 'platelet activation markers' in disease states [33] .
